[1] Dhanasekaran R, Limaye A, Cabrera R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics[J]. Hepat Med, 2012, 4(6): 19-37. [2] 蔡永娥, 乔建锦, 孙晓茹, 等.我国原发性肝癌研究进展[ J] .2008 ,16(1):141 [3] 贾志凌, 王莉, 刘畅, 等.甲胎蛋白异质体对肝癌诊断的临床意义[J] .中国肿瘤,2010 , 19(10):686 . [4] Mao Y, Yang H, Xu H, et al. Golgi protein 73(GOLPH2) is a valuable serum marker for hepatocellular carcinoma[J]. Gut, 2010, 59(12):1687-1693. [5] 朱国民, 周晓庆, 林长青, 等.新肝癌标志物高尔基体蛋白GP73在肝癌血清学诊断中的应用[ J] .中华医院感染学杂志, 2010 , 20(15):2350 . [6] 陈贞,龙璐,陶亚,等. 血清ALP,GGT,5'-NT与AFP联合检测在原发性肝癌诊断中的价值[J].实用预防医学,2012,11(4): 22-25 [7] 邓广博. AFP和高尔基体糖蛋白-73联合检测诊断原发性肝癌临床评价[J].中国肝脏病杂志(电子版),2014,6(4):68-70. [8] Tian L, Wang Y, Xu D, et al. Serological AFP/golgi protein 73 could be a new diagnostic parameter of hepatic deseases[J]. Int J Cancer,2011, 129(8): 1923-1931. [9] Marrero JA, El-Serag HB .Alpha-fetoprot ein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases[J] .Hepatology, 2011 ,53(3):1060 [10] 侯旭, 刘凯, 王广义, 等. GP73 联合AFP 检测价值及肝细胞癌早期诊断和复发监测的研究进展[J]. 中国普通外科杂志, 2011,20(7): 768-770. [11] 杨收平, 李海英. 血清AFP 和高尔基体蛋白73 联合检测对原发度肝癌的诊断价值[J]. 重庆医学, 2012, 41(27): 2880-2882. [12] 孔祥亘, 韩绍磊, 郑昭敏, 等.高尔基体蛋白73 联合甲胎蛋白异质体在原发性肝癌诊断中的价值[J] .山东大学学报(医学版),2011 , 49(4):110 . [13] 毛一雷,杨华瑜,徐海峰. 肝细胞肝癌新的血清标记物GP73. 第十二届全国肝癌学术会议论文汇编, 2009: 52-53. [14] Yamamoto K, Imamura H , Matsuyama Y, et al.AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathologicalvariables of HCC[J] .Journal of Gastroenterology, 2010 , 45(12):1272-1282 . [15] 王祖森,吴力群,李玉军,等. AFP 血清浓度及肝癌组织中Cx43的表达与肝癌根治切除后早期复发和预后的关系[J].中华普通外科杂志,2012,27(10):816-820．
2016, Vol. 23 
